Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in Start Up

Executive Summary

With so much genomics data and putative drug targets to sift through, drug developers cannot risk making research resource allocation decisions before correlating gene and protein function with a disease process. The need has spawned a new generation of post-genomics companies focused on developing tools for validating drug targets, including smart screening methodologies and cell-based assays, and on ways to better organize and characterize genomics and proteomics data.

You may also be interested in...

EraGen Biosciences

EraGen is developing hardware and software tools for genomics analysis including Master Catalog, a web-based tool that combines genomic database organization and search capabilities with evolutionary biological information, and AEGIS, a technology for direct DNA detection without the need for target amplification.

Cellular Genomics

Cellular Genomics discovers and validates new drug targets, initially those associated with dendritic cells, T cells, and mast cells. It is carrying out classical cell biology studies in parallel with genomic analysis, thereby correlating changing cellular behavior with changes in patterns of gene expression and in protein modification and localization within the cell.

Epigenomics GMBH

Epigenomics is developing diagnostics based on individuals' genetic profiles. Its core technology is based on measurements of DNA methylation: the company believes methyl groups, which stick up like flags from stretches of DNA, may indicate the absence or presence of disease.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts